FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...
GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...
Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...
Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction ...
We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...
The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...
At virtually every stage of the processes required to bring a new drug to market—from early discovery through clinical trials—biopharma scientists would like more information. More insight into the ...
Bioanalytical method development and validation are at the forefront of ensuring rigorous, reproducible and reliable data in both drug development and clinical diagnostics. The field encompasses the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results